Trial registration: The study was registered at ClinicalTrials.gov, NCT03954275.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
GFR
Glomerular filtration rate
ARC
Augmented renal clearance
CrCl
Creatinine clearance
ICU
Intensive care unit
CrCl24h
Measured 24-h urinary creatinine clearance
CG
Cockcroft–Gault formula
CKD-EPI
Chronic Kidney Disease Epidemiology Collaboration formula
MDRD
Modification of Diet in Renal Disease Study formula
Estimators of glomerular filtration rate (GFR) have been shown to be flawed in critically ill patients, especially for augmented renal clearance (ARC), commonly defined as a measured urinary creatinine clearance (CrCl) ≥ 130 ml/min/1.73 m2 [1]. Therefore, measuring CrCl should be performed in daily practice on the intensive care unit (ICU). However, many ICUs still rely on estimating formulae to monitor GFR [1, 2]. As estimators underestimate measured CrCl in ARC patients, ARC might remain unrecognized and lead to subtherapeutic plasma levels of drugs with predominant renal clearance [3]. Therefore, the aim of this study is to define the most precise GFR estimator, which can then be used to detect ARC when measured CrCl is unavailable.
We performed a multicenter retrospective registry-based [4] cohort study in adult ICUs from 3 tertiary university-affiliated hospitals in Belgium (Leuven, Ghent, Antwerp). All consecutive patients admitted between January 2013 and December 2015 were screened for eligibility. All patients ≥ 18 years old and having at least one measured 24-h urinary CrCl (CrCl24h) were included. Agreement between CrCl24h and formulae estimating renal function, i.e., Cockcroft–Gault (CG), Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI), and Modification of Diet in Renal Disease Study (MDRD), was evaluated on all included ICU days. For the estimator with the best precision, a cut-off for ARC with optimal specificity and sensitivity was identified, by calculating the Youden index [5]. Predictions for ARC using the cut-off value were compared to the actual presence of ARC based on the CrCl24h. Cut-off values with either very high sensitivity (> 95%) or specificity (> 95%) were also identified. Finally, the performance of these cut-offs was evaluated in an external single-center (Leuven, January 2016–December 2016) validation set by receiver-operating characteristics (ROC) curve analysis, using 2000 bootstrap replicates. The same inclusion and exclusion criteria as described above were applied.
Anzeige
A total of 51,604 ICU days were included to define a cut-off. Agreement analysis between CrCl24h, the clinical reference, and the formulae estimating renal function is shown in Table 1. None of the estimators were precise (i.e., standard deviation of the mean bias was large for all estimators), with the CKD-EPI formula performing best over the whole CrCl24h range, and for ARC specifically, as illustrated in Fig. 1a. Hence, the CKD-EPI formula was selected for further analysis. In the validation set, 10,503 ICU days were included. For the CKD-EPI formula, the optimal cut-off for ARC was 96.5 ml/min/1.73 m2. This cut-off showed a sensitivity of 86.6% [85;88.1] and a specificity of 71% [70;71.9]. The cut-off values with very high sensitivity and specificity were 87.3 ml/min/1.73 m2 (sens, 95.8% [95;96.7]; spec, 57.6% [56.6;58.7]) and 125.2 ml/min/1.73 m2 (sens, 31.4% [29.4;33.5]; spec, 95.2% [94.7;95.6]), respectively. The ROC curve analysis including the cut-off values is shown in Fig. 1b. Evaluating the optimal cut-off in the validation set, we found that the proportion of accurate predictions for ARC decreased during the first 2 weeks of ICU stay. The is due to an increased false positive rate (Day-1, 16%; Day-14, 49%).
Table 1
Agreement analysis between CrCl24h and formulae estimating renal function
All ICU days (n = 51,604)
CrCl24h < 130 ml/min/1.73 m2 (n = 41,290)
CrCl24h ≥ 130 ml/min/1.73 m2 (n = 10,314)
Median (IQR) (ml/min/1.73 m2)
CrCl24h
73 (37;118)
58 (30;88)
166 (145;200)
CrClCG
83 (50;127)
70 (43;103)
145 (116;183)
eGFRMDRD
87 (50;130)
72 (42;109)
143 (115;185)
eGFRCKD-EPI
88 (51;108)
75 (43;99)
116 (104;130)
Correlation with CrCl24h = Spearman correlation coefficient
CrClCG
0.63°
0.62°
0.18°
eGFRMDRD,
0.59°
0.60°
0.15°
eGFRCKD-EPI
0.69°
0.72°
0.19°
Mean bias (95% CI) = mean difference CrCl24h – estimator (ml/min/1.73 m2)
CrClCG
− 11 (− 11;-10)
− 20 (− 20;-19)
25 (23;27)
eGFRMDRD
− 14 (− 15;− 14)
− 23 (− 23;− 23)
21 (19;23)
eGFRCKD-EPI
3 (3;4)
− 12 (− 13;− 12)
66 (64;67)
Precision = SD of the bias (ml/min/1.73 m2)
CrClCG
55
41
83
eGFRMDRD
61
46
94
eGFRCKD-EPI
48*
26*
62*
Accuracy = percentage within 30% of CrCl24h
CrClCG
47
45
58
eGFRMDRD
45
43
56
eGFRCKD-EPI
50
51
45
n number of ICU days; CrCl24h creatinine clearance measured by 24-h urine collection, corrected for body surface area; IQR interquartile range; CrClCG estimated creatinine clearance by the Cockcroft – Gault formula, corrected for body surface area; eGFRMDRD estimated glomerular filtration rate by the 4-variable Modification of Diet in Renal Disease formula; eGFRCKD-EPI estimated glomerular filtration rate by the Chronic Kidney Disease Epidemiology Collaboration formula; SD standard deviation; CI confidence interval
°p < 0,001
*Best performing
Fig. 1
a Bias in function of CrCl24h for the three formulae estimating renal function. Top: MDRD (ml/min/1.73 m2); mid: CG corrected for a body surface area of 1.73 m2 (ml/min/1.73 m2); bottom: CKD-EPI (ml/min/1.73 m2). b Receiver operating characteristics curve analysis for the CKD-EPI formula. The shaded area represents the 95% confidence intervals. The dots represent the cut-off values for optimized sensitivity and specificity, very high (> 95%) sensitivity and very high (> 95%) specificity
×
Overall, there was poor agreement between CrCl24h and GFR estimators, confirming previous literature [1]. However, the CKD-EPI formula, which is the “least worse” alternative to CrCl24h, provided a cut-off with reasonable performance to detect ARC. Depending on the clinical context, this cut-off can be adapted to increase sensitivity or specificity. When applying this cut-off, the user should note that the accuracy decreases over time during the first 2 weeks of ICU stay. Hence, its largest benefit lies in the beginning of ICU stay. The presented CKP-EPI cut-off can be used to guide upfront increased antimicrobial dosing in patients presenting with ARC early upon ICU admission, when CrCl24h is not available.
Acknowledgements
The authors would like to thank the members of the M@tric research group for helpfully providing the M@tric database. The authors would also like to thank Astrid Eggerickx for her contribution to the analysis of the multicenter cohort.
Ethics approval and consent to participate
M@tric data-collection has ethical committee approval from the University Hospitals Ghent, where the database is being hosted (PA 2009/006). Research on the M@tric database requires ethical committee approval of the ethical committee of one of the contributing centers which then independently acts as central ethical committee.
Anzeige
Approval for the present study was obtained from the ethical committee of the University Hospitals Leuven (S61364) for the use of the M@tric dataset, as well as the retrospective Leuven dataset. This research has been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
